Compare Alcon AG (ALC) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.46. The key difference: Alcon AG pays a 0.54% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | BIL | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Fixed Income |
52-Week High | $92.22 | $91.77 |
52-Week Low | $62.02 | $91.27 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
BIL trades at $91.43, down slightly by 0.01% over 24 hours, with a bearish technical outlook indicated by moving averages. The ETF maintains a consistent dividend payout of $0.27 per share, with recent distributions in H1-26 and upcoming in H2-26. Market sentiment is influenced by Federal Reserve rate hike speculation, as bond ETF inflows surge amid inflation concerns and stock volatility.
The outlook for BIL is cautious due to potential interest rate hikes in 2026, which could impact short-term Treasury yields. Risks include Fed policy uncertainty and macroeconomic shifts, but the ETF offers stability through regular dividends. Investors should weigh yield opportunities against interest rate sensitivity in the current environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
